Vacinas e Componentes

DNA.SV40 (4) Grafeno (7)

JAPS – Integração genómica da VAX – Gene Expression Alterations Induced by mRNA Vaccines

Nicolas Hulscher, Peter A. McCullough, John A. Catanzaro · 2026

Ler artigo

Messenger RNA (mRNA) vaccines harness host cellular machinery to produce antigenic proteins, but…

Autoimmunity – Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada

Vacinas e Componentes

David J. speicher, Jessica Rose, Kevin McKernan · 2025

Ler artigo

For some of the cOViD-19 vaccines, the drug substances released to market were…

PUBMED – OpenSAFELY: Effectiveness of COVID-19 vaccination in children and adolescents

Vacinas e Componentes

Colm D Andrews, Edward P. K. Parker, Elsie Horne, Venexia Walker, Tom Palmer, Andrea L Schaffer, Amelia CA Green, Helen J Curtis, Alex J Walker, Lucy Bridges, Christopher Wood, Victoria Speed, Christopher Bates, Jonathan Cockburn, John Parry, Amir Mehrkar, Brian MacKenna, Sebastian CJ Bacon, Ben Goldacre, Miguel A Hernan, Jonathan AC Sterne, The OpenSAFELY Collaborative, William J Hulme · 2024 / 2025

Ler artigo

Children and adolescents in England were offered BNT162b2 as part of the national…

NEJM – Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Vacinas e Componentes

E.J. Anderson, N.G. Rouphael, A.T. Widge, L.A. Jackson, P.C. Roberts, M. Makhene, J.D. Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A.B. McDermott, B. Flach, B.C. Lin, N.A. Doria-Rose, S. O’Dell, S.D. Schmidt, K.S. Corbett, P.A. Swanson II, M. Padilla, K.M. Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, K. Cross, V.V. Edara, K. Floyd, M.S. Suthar, D.R. Martinez, R. Baric, W. Buchanan, C.J. Luke, V.K. Phadke, C.A. Rostad, J.E. Ledgerwood, B.S. Graham, J.H. Beigel · 2020

Ler artigo

Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus…

IJVTPR – Safety of mRNA Injectables Administered During the First Twenty-Four Months of the International COVID-19 Injection Program

Vacinas e Componentes

Eliana Romero, Shawn Fry, Brian Hooker · 2023

Ler artigo

Two mRNA-based COVID injectables were granted emergency use authorization in both children and…

IJVTPR – What Is in the So-called COVID-19 “Vaccines”? Part 1: Evidence of a Global Crime Against Humanity

Vacinas e Componentes

David A. Hughes · 2022

Ler artigo

Between July 2021 and August 2022, evidence of undisclosed ingredients in the COVID-19…

MEDxRIV – Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine

Vacinas e Componentes

Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, James F. Simon, Amanda Hagen, Steven M. Gordon · 2023

Ler artigo

The purpose of this study was to evaluate whether a bivalent COVID-19 vaccine…

IJVTPR – Real-Time Self-Assembly of Stereomicroscopically Visible Artificial Constructions in Incubated Specimens of mRNA Products Mainly from Pfizer and Moderna

Vacinas e Componentes

Young Mi Lee, Daniel Broudy · 2024

Ler artigo

Observable real-time injuries at the cellular level in recipients of the “safe and…

JAMA – Interim Estimated Effectiveness of 2025-2026COVID-19 Vaccines in Adults Using a Test-Negative Design

Vacinas e Componentes

Ryan E. Wiegand; Sean Chickery; Duck-Hye Yang; Sarah W. Ball; Malini B. DeSilva; Kristin Dascomb; Stephanie A. Irving; Karthik Natarajan; Nicola P. Klein; Shaun J. Grannis; Toan C. Ong; Elizabeth A. K. Rowley; Adam Yates; Yan Zhuang; Sarah Wilson; Charlene E. McEvoy, MD; Inih J. Essien, OD; Omobosola O. Akinsete, MBBS, MPH; Allison L. Naleway, PhD; Padma Koppolu, MPH; Ousseny Zerbo, PhD; John R. Hansen, MPH; Karen B. Jacobson, MD, MPH; Lawrence Block, MPH; Brian E. Dixon, PhD; Thomas Duszynski, PhD; Colin Rogerson, MD, MPH; Michelle A. Barron, MD; Catia Chavez, MPH; Josephine Mak, MPH; Allison Avrich Ciesla, PhD; Monica Godfrey, MPH; Amber Kautz, PhD; Morgan Najdowski, MPH; Ruth Link-Gelles, PhD, MPH; Jennifer DeCuir, MD, PhD; Amanda B. Payne, PhD, MPH · 06/28/2026

Ler artigo

The 2025-2026COVID-19 vaccine, targeting JN.1 and JN.1-derived sublineages, became available in the US…